Latest News

Veligrotug-vvze is the first FDA-approved thyroid eye disease treatment with data in both active and chronic disease.

A combination regimen of azacitidine, venetoclax, and gilteritinib shows encouraging benefits in patients with newly diagnosed FLT3-mutated AML who were ineligible for intensive chemotherapy.

Biosimilars are equally safe and cut costs. Pharmacists can ease patient fears at the counter.

Priority review NDA puts oral SERD giredestrant on PDUFA track for ER-positive, HER2-negative breast cancer, after reduced recurrence risk in lidERA trial.

In an interview with Pharmacy Times, Caitlin Jones, PhD, discusses why high-risk, low-benefit treatments for chronic low back pain require greater scrutiny.

Interim data, briefly held back from the CDC’s weekly report, show the reformulated shot added meaningful protection even among adults with substantial existing immunity.

Compared with placebo, adult patients with ADHD and comorbid anxiety had greater change from baseline in AISRS total score at week 8.

In an interview with Pharmacy Times, Alison Newman, MPH, program operations specialist with the Center for Community-Engaged Drug Education, Epidemiology & Research at the Addictions, Drug & Alcohol Institute at the University of Washington, discusses the significance of OTC naloxone availability and the barriers that remain despite the introduction of additional products.

The European Commission approved tolebrutinib as the first therapy targeting disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (SPMS).

Evaluating, implementing, and optimizing automation technologies that improve safety, efficiency, and patient care outcomes are practical strategies for health-system pharmacy leaders.

This FAQ outlines current measles cases, key drivers of increasing cases, and the essential role pharmacists play in vaccination, patient counseling, case recognition, and combating vaccine misinformation.

Supported by improved progression-free survival outcomes in the phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, sacituzumab govitecan-hziy received FDA approval as both a monotherapy and combination therapy with pembrolizumab.

Pharmacists who understand the workflow before July 1 will be the ones patients and prescribers depend on when the program launches.

The FDA grants fast track designation to VS-7375, an oral KRAS G12D dual ON/OFF inhibitor, advancing new hope for pretreated non–small cell lung cancer (NSCLC).

The agent is to be used alongside diet adjustments in adult patients.

The FDA approved palbociclib-based maintenance therapy for HR-positive, HER2-positive advanced breast cancer following a significant progression-free survival benefit in PATINA.

As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.

Marijuana’s move to Schedule III has reignited a long-standing contradiction.

Pharmacists should be up-to-date on current outbreak status, US risk level, and how to recognize warning signs and counsel concerned patients as confirmed Ebola cases caused by Bundibugyo ebolavirus continue to rise across the Democratic Republic of the Congo (DRC) and Uganda.

The new indication is for those aged 12 years and older with unresectable or metastatic SS who received prior chemotherapy and are positive for certain genetic subtypes.

On GLP-1s like semaglutide or tirzepatide, weight loss can mean muscle loss; encourage patients to use protein and resistance training to stay strong.